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Studies of the pathogenesis of cystic fibrosis (CF) and primary
ciliary dyskinesia (PCD), as well as novel genetic mouse models,
vividly illustrate that effective “mucus clearance” is a critical
innate airway defense mechanism. Modern physics, physical
chemistry, biochemistry, and cell and systems biology are reveal-
ing the structure of the mucus clearance apparatus and elucidat-
ing key parameters underlying its efficient function. New para-
digms are evolving to describe the interaction of the near-cell
surface environment with overlying mucus, the dominant role
of adequate hydration for effective mucus clearance, the role of
nucleotide and nucleoside signaling to regulate airway surface
hydration, the physiochemical basis of mucus adhesion, and the
pathophysiologic consequences of impaired mucus clearance.
The recent success of hypertonic saline to restore surface hydra-
tion and improve mucus clearance in CF suggests that novel
therapeutic strategies will be similarly efficacious in other airway
diseases, including chronic obstructive pulmonary disease (COPD).
Keywords: chronic bronchitis; cystic fibrosis; primary ciliary dyskinesia
HISTORICAL PERSPECTIVE AND INTRODUCTION
A coordinated system of epithelial water and ion transport, mu-
cin secretion, cilia action, and cough, collectively termed “mucus
clearance,” results in the continuous flow of fluid and mucus over
airway surfaces. The study of mucus clearance has a fascinating
history, and was investigated using “classical” particle clearance
physiologic techniques 25–30 yr ago (reviewed in Ref. 1). Despite
advances made by pioneering scientists, it was clear that “the
factors which normally control [airway surface liquid] secretion
in such a manner as to prevent flooding or drying of the airways
and facilitate mucociliary transport are still largely unknown”
(2). Subsequently, mucus clearance per se has received less atten-
tion, as greater emphasis was placed on cellular and molecular
aspects of pulmonary pathophysiology. Furthermore, the patho-
genic importance of mucus transport was questioned due to
minimal impact of mucolytic therapy on airway diseases. From
her early work on the lungs’ secretory apparatus (3), to her
generation of valuable tools to study mucous cells (4, 5), through
her landmark cloning of the MUC5AC promoter (6), and recent
studies of detailed signal transduction mechanisms in bacterial
infection (7) and after smoke exposure (8), it is clear that Carol
B. Basbaum recognized the importance of mucus clearance for
respiratory health. We consider it an honor and privilege to
summarize recent advances in the field of mucus clearance as a
tribute to her in the American Journal of Respiratory Cell and
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Molecular Biology. Rather than a comprehensive review of the
entire field and its literature, we present eight topics that build
on recent observations and also point toward future studies
needed to advance this field. As background, it is important to
understand that water transport across the apical plasma mem-
brane of airway epithelial cells, and thus the hydration status of
airway surface liquid (ASL), is principally regulated by Cl ion
export through both the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) and Ca activated chloride channels
(CaCC), and by Na influx through the epithelial Na channel
(ENaC) (Figure 1).
INNATE DEFENSE OF AIRWAY SURFACES AGAINST
INHALED BACTERIA/YEAST/FUNGI/PARASITES IS A
MULTI-TIERED PROCESS, BUT MECHANICAL
CLEARANCE IS PARAMOUNT
Chronic bacterial infection of airways is usually associated with
obstruction, which can be produced by tumors or foreign bodies,
but is most commonly caused by mucus adhesion, formation of
mucus plaques, and ultimately mucus plugs. Genetic diseases
characterized by this phenomenon include CF and PCD (Figures
2A and 2B). In addition, recent evidence from the laboratory
of Dr. Hogg and colleagues (9) suggests that mucus obstruction
contributes to the pathogenesis of COPD (Figure 2C). These
clinical observations are complemented by data from animal
models of disease. Typically, chronic airway infection in a labora-
tory animal requires the administration of bacteria in a milieu
designed to obstruct an airway lumen—for example, agarose
beads (10). More recently, transgenic mice that overexpress the
 subunit of ENaC revealed a phenotype in which depletion of
ASL produced mucus adhesion, plaque and plug formation, and
a reduced ability to clear inhaled bacteria (11) (Figure 2D). In
contrast, diseases that affect other aspects of lung defense—for
example, dysfunction of alveolar macrophages, neutrophils, or
B-cells (both secretory IgA, and IgG)—tend to produce alveolar,
rather than airway, pathology. These observations suggest that
mechanical clearance is the dominant form of airway innate
defense, and that failure of mucus clearance produces obstruc-
tion and predisposes to chronic bacterial infection.
THE MUCUS CLEARANCE SYSTEM REQUIRES
TWO LAYERS: A LUBRICATING PERICELLULAR
ENVIRONMENT AND AN OVERLYING MUCUS LAYER
Efficient clearance from airway surfaces requires the coordinated
interaction of two separate layers that together comprise ASL: an
overlying transported mucus layer and a separate, distinct envi-
ronment near the cell surface. The mucus layer must bind and
entrap virtually all deposited particles. Its viscoelastic properties
facilitate conversion of energy from beating cilia into vectorial
mucus transport and should also be amenable to clearance by
cough under periods of stress. The long-standing concept was
that a low-viscosity aqueous environment, termed the “sol” or
“periciliary liquid” layer, surrounded the cilia, in which they
could freely beat. However, this concept never explained how
the height of the layer varied from cell type to cell type, for
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Figure 1. A depiction of ion transport across the apical plasma mem-
brane of airway epithelial cells. Schema describing extracellular nucleo-
tide/nucleoside biochemical networks, sensors (receptors), and regula-
tory paths controlling effectors (ion channels). Cl can egress through
CFTR after adenosine stimulation of A2b-R or through CaCC after stimu-
lation of P2Y2-R by ATP. Na transport is facilitated by ENaC. CF cells
will not be able to mount a Cl response after adenosine due to the
absence of functional CFTR. Finally, adenosine (ADO) and inosine (INO)
are removed from the airway surface by concentrative nucleoside trans-
porters (CNTs) (63).
example 7 m over ciliated cells and 3 m over goblet or noncili-
ated brush cells (12), or that electron microscopy after specific
types of fixation revealed a complex architecture in this domain
(Figure 3). Another conundrum emanated from studies of indi-
Figure 2. Histologic evidence for mucus plugging in bronchioles. In
early (A ) and late (B ) CF and in COPD (C ) terminal bronchioles are
obstructed with mucoid secretions, as is a larger airway in the ENaC
transgenic mouse (D ). A, C, and D are reproduced from Refs. 64, 9,
and 11, respectively, with permission.
viduals with Type I pseudohypoaldosteronism (PHA), who fail
to absorb liquid from airway surfaces due to genetic defects in
ENaC (13). Previously, it was postulated that excess ASL would
cause the mucus layer to “float off” cilia tips, reducing mucus
transport. Strikingly, PHA patients with “excessively wet” air-
way surfaces also exhibited the fastest rates of lung particle
clearance yet reported (13). Subsequent in vitro studies revealed
that liquid added to airway surfaces selectively entered the mu-
cus layer, causing it to swell and maintain a connection between
cilia and mucus, such that mucus transport rates actually in-
creased when liquid was added (14). The near cell ASL layer is
likely comprised of tethered mucins and other molecules such
as cell surface glycolipids, while the overlying layer consists of
high-molecular-weight mucin dimers and trimers, 0.5–20 M
long, interacting with globular proteins (Figure 4). The nonmucin
interacting proteins may serve as cross-links and/or provide other
innate defense activities. The near-cell environment likely pro-
vides an architectural framework for the movement of water,
imparts lubricating activity (15), and serves as a selective filter
that restricts particle access to cell surfaces.
ADEQUATE HYDRATION OF THE MUCOSAL SURFACE
IS ESSENTIAL FOR NORMAL MUCUS CLEARANCE
In general, the hydration of mucosal surfaces determines the
efficiency of mechanical transport, for example, during blinking
and swallowing. It was widely assumed that ciliary activity and
mucin secretion were the major determinants of airway mucus
clearance. While both are important, the balance of evidence
suggests that hydration is the dominant variable governing mu-
cus clearance. Individuals with CF, who exhibit a phenotype
thought to reflect ASL volume depletion (16), develop more
rapid and severe airway infection and destruction than patients
with PCD, who have dysfunctional cilia. Asthma, which is clearly
characterized by hypersecretion of mucin, is not associated with
bacterial infection.
Further evidence for the dominant role of hydration status
in mucus clearance comes from mouse models. A series of mice
with either no cilia or dysfunctional cilia exhibited surprisingly
Figure 3. Perfluorocarbon-osmium fixed mouse trachea as studied by
transmission electron microscopy reveals an organized structure in the
extracellular space surrounding the cilia and microvilli. Luminal air is
above and the apical cell surface is at the bottom. (Courtesy of Dr. R.
Pickles, the University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina.)
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Figure 4. The two-layer model of mucus innate defense.
The near-cell surface domain around the cilia and microvilli
(periciliary layer  PCL) contains cell surface tethered
mucins and other molecules such as glycolipids. The overly-
ing mucus layer is functionally organized by secreted, gel-
forming mucins (long strands) interacting with globular
proteins to produce the viscoelastic properties required for
particle retention and transport.
little or no pulmonary disease phenotype (17). Similarly, antigen-
or cytokine-induced animal models resulting in hypersecretion
of mucin exhibit relatively little airways obstruction or infection
(18). In contrast, overexpression of the  subunit of ENaC in
murine airways reduced periciliary volume, slowed mucus clear-
ance, caused mucus adhesion (Figure 2D), and resulted in spon-
taneous mortality of  60% by 30 d of age due to mucus obstruc-
tion/asphyxia (11).
As shown in Figure 5, an integrated model of the airway
pericellular environment and overlying mucus layer, incorporat-
ing the functional requirement for adequate hydration, recon-
ciles previous discrepancies related to mucus transport. In this
model, the mucus layer acts as a fluid reservoir and, within
physiologic limits, it accepts or donates liquid to maintain apposi-
tion of the mucus layer inner surface with the tips of the cilia.
Thus, instead of excess fluid floating mucus off the cilia and
slowing mucus clearance, mucus swells and clearance accelerates
when liquid is added to the lumen, as confirmed in human airway
epithelial cell cultures (14). Conversely, under conditions of rela-
tive dehydration, mucus can donate water to preserve periciliary
liquid layer hydration. However, when the airway surface be-
comes severely dehydrated, as in humans with CF and in ENaC
transgenic mice, the ability of the mucus layer to “donate” water
is exhausted. The periciliary layer collapses, and the viscous,
adhesive mucus layer forcibly interacts with cell surface mucins
(19), resulting in adhesion and decreasing mucus clearance, ulti-
mately forming plaques and plugs of concentrated mucus (11).
AIRWAY SURFACE HYDRATION IS REGULATED BY
RELEASE AND METABOLISM OF NUCLEOTIDES
Extracellular nucleotides (ATP, UTP, and UDP) and nucleo-
sides (adenosine), acting on specific receptors (P2Y2–R [ATP/
Figure 5. The role of water in the struc-
ture and function of the “two-layer” mu-
cus clearance system. Under normal con-
ditions (center panel), there is sufficient
water to hydrate the periciliary layer and
mucus layer and mucus transport pro-
ceeds at normal rates (60 m/s). Addition
of water (and salt) to the surface selec-
tively swells the mucus layer, maintaining
apposition of the mucus and periciliary
layers (left panel). Reduction in viscoelastic-
ity may account for the observed accelera-
tion of mucus transport ( 100 m/s) un-
der highly hydrated conditions. Loss of
water (and salt) from the airway surface
collapses both the periciliary and mucus
layers, producing mucus adhesion to cell
surfaces (right panel).
UTP], P2Y6–R [UDP], and A2b–R [adenosine]), stimulate Cl
transport when administered to the airway lumen (20). The ob-
servation that P2Y2-R activation not only initiates Cl secretion,
but also reciprocally inhibits Na absorption (21, 22), strongly
suggests the importance of these molecules to finely tune ASL
height and volume. Indeed, recent studies using well-differenti-
ated human airway epithelial cell cultures that recapitulate the
morphology, ASL volume homeostasis, and mucus transport
functions of the intact epithelium (Figure 6) suggest that the
formation of ASL absolutely requires the release, metabolism,
and retention of nucleotides and nucleosides on airway surfaces.
As shown in Figure 7, a typical experiment involves addition of
a small volume of physiologic solution to the airway surface,
and ASL height is followed with confocal microscopy until a
steady state is achieved. Under static conditions, normal airways
epithelia adjust Na and Cl transport so that the periciliary
liquid layer approximates the height of the outstretched cilia
(14). ATP and adenosine measurements in ASL, under static
conditions, revealed ATP levels below those expected to activate
P2Y2-R ( 1 nM), whereas adenosine was in the concentration
range expected to activate A2b–R ( 40–50 nM). Addition of
adenosine deaminase, which metabolically removes adenosine,
or 8-SPT, an inhibitor of adenosine receptors, resulted in
unrestrained Na absorption and ASL collapse (23). These re-
sults suggest that under static conditions, ATP is released onto
the airway surface (estimated rate  300–400 fmoles/cm2/min),
where it is metabolically converted into adenosine, which binds
the A2b–R, in turn activating CFTR, which serves as a Cl secre-
tory channel and also inhibits ENaC. The net effect is to balance
absorption and secretion to maintain an adequate volume of
liquid for efficient mucus transport on the airway surface. We
speculate that constitutive ATP secretion, perhaps via vesicle
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Figure 6. Cell culture/physiologic system to measure ASL
volume homeostasis and mucus transport in well-differenti-
ated human bronchial epithelial (HBE) cells. (A ) Perfluoro-
carbon/osmium fixed HBE culture demonstrating excellent
cellular differentiation and discrete periciliary (PCL) and
mucus layers. (B ) Living HBE culture with cellular (calcein-
green) and ASL compartments (Texas-red dextran) labeled
and visualized with x-z confocal microscopy. (C ) En face
view of culture with fluorescent beads trapped in mucus
as viewed with time lapse fluorescence microscopy to mea-
sure rotational mucus transport. (D ) Measurement of ASL
height by confocal microscopy and transepithelial electric
potentials (Vt) by microelectrodes to measure ASL volume
and ion transport homeostasis.
release, is an intrinsic mechanism to hydrate airway surfaces and
maintain basal mucus clearance.
Mechanotransduction is the process by which physical forces
are translated to physiologic responses and is widely important
in tissue homeostasis. Recent studies strongly suggest that phasic
motion of the airway wall during lung inflation/deflation regu-
lates ASL homeostasis via nucleotides and nucleosides (19).
When normal human airway epithelial cells were subjected
to phasic shear stresses similar to those achieved during tidal
breathing, the height of ASL doubled, when compared with static
conditions (Figure 8). Direct measurements revealed that ATP
rose to  30–40 nM in response to shear stress, which is sufficient
to activate P2Y2-R, and that adenosine concentrations doubled
to  160 nM (Figure 8). These studies confirm the importance
of extracellular nucleotides and nucleosides to generate an ASL
environment capable of mucus transport. Thus, normal human
airway epithelia control ASL hydration via complementary path-
ways: ATP via P2Y2-R, and adenosine, the metabolic product of
ATP, via A2b-R. In CF, CFTR is not “available” for activation
by adenosine, and ASL hydration is proportionate solely to ATP
on airway surfaces. Thus, the CF lung is uniquely vulnerable to
insults that reduce ATP on airway surfaces.
Figure 7. ASL volume (height) regulation by normal
HBE cultures under static conditions. (A ) ASL height
measured by x-z confocal microscopy at t  0 after
addition of 20 l of PBS. (B ) Mean data for ASL volume
homeostasis after addition of PBS without (squares) or
with (triangles) 8-SPT (105 M) at 48 h. The blue area
depicts normal periciliary liquid layer height. (C ) Confo-
cal images of ASL at 48 h without (top panel) and with
(bottom panel) 8-SPT. The 3-m level in the 8-SPT group
represents the minimum volume on the airway surface,
when liquid is trapped within flattened cilia. Adapted
from Ref. 19, with permission.
INADEQUATE HYDRATION CAUSES MUCUS
ADHESION TO EPITHELIAL SURFACES, RESULTING IN
OBSTRUCTION AND INFLAMMATION, AND SERVING
AS A NIDUS FOR INFECTION
Mucus adhesion likely contributes to the pathophysiology of lung
disease in several different ways. Recent studies by Dr. Hogg and
colleagues found that pack-years of cigarette smoking was directly
correlated with epithelial hyperplasia and mucus obstruction (9).
In the ENaC mouse, mucus adhesion leads to the formation
of mucus plugs that can be sufficiently severe to asphyxiate these
animals (11). The failure of mucus clearance in ENaC mice may
directly produce chronic neutrophilic inflammation. Neutrophils
have been observed in bronchoalveolar lavage fluid of patients
with CF without apparent infection, which may be a consequence
of viscous, static mucus, although an intrinsic CF airways hyper-
inflammatory state or undiagnosed infection is also possible (24).
It stands to reason that proinflammatory stimuli will become
more concentrated and linger in a lung with ASL dehydration
and static mucus. Thus, stimuli that are insufficient to induce
inflammation in a normal lung, with adequate fluid transport over
airway surfaces, may cause inflammation and self-reinforcing
pathologic sequelae in a lung with impaired mucus clearance.
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Figure 8. ASL volume is increased in normal HBE cultures subjected to
phasic motion. The dark blue line represents ASL height after addition
of 20 l of PBS to the apical surface and maintained under phasic
motion conditions. The light blue area depicts the normal height of the
periciliary layer under static conditions.
Perhaps the most important pathophysiologic effect of adher-
ent mucus is that it is the site of chronic bacterial infection in
the airways (Figure 9). Quantitative studies in CF airways show
that infection centers on intraluminal mucus, with virtually no
bacteria detected adherent to, or within, epithelial cells (25).
Bacteria may adapt and survive in static mucus due to production
of mucinases that help them gain nutrition. Indeed, the interac-
tion of bacteria and static mucus is complex. For example, O2
gradients are generated in macroscopic mucus plaques, reflecting
both long O2 diffusion distances and high rates of epithelial
O2 consumption (25, 26). Bacterial communities in the airway
lumens of patients with CF are likely thriving in an anaerobic
environment (27). Physical chemical studies of mucus and calcu-
lations of O2 diffusivity and bacterial O2 consumption predict
frankly anaerobic niches within mucus plaques. Mucus concen-
tration (% solids) also may be important for the mode of bacte-
rial growth. Specifically, the width of the mucin mesh or “pore
size” varies dramatically with hydration status. In normal mucus,
widths of 5–15 m are observed, which foster bacterial motility
Figure 9. Intraluminal mucus is site of airways infection in CF. (A ) Low
power H&E view depicting multiple bacterial colonies (arrows) within
luminal mucopurulent material. (B ) Higher power H&E view showing
robust neutrophil infiltration (arrowheads) through the epithelium and
a bacterial colony within mucus (arrow). (C ) Alcian yellow-toluidine
blue stain of bacteria within intraluminal macrocolony.
and also enable quorum factors needed for biofilm formation
to freely diffuse away (28). Both processes favor planktonic
bacterial physiology, which will enhance bacterial exposure to
antimicrobial substances and allow phagocytic cells to access,
engulf, and kill bacteria (28). Conversely, in concentrated mucus,
the apparent mesh size decreases below the size of a bacterium
( 200 nm), limiting bacterial motility and egress of quorum
factors. Coupled with the inability of soluble antimicrobial fac-
tors and neutrophils to penetrate and kill bacteria enmeshed in
thick mucus, the thick mucus environment likely enhances bio-
film growth. Finally, limited water availability may become a
selective pressure for bacteria that thrive in relatively dry, anaer-
obic environments, including soil bacteria such as Burkholderia
cepacia, resulting in the characteristic and unusual microbiology
in the CF lung (27, 29). Similar phenomena, but accordingly
less intense, may occur in the airways of patients with non-CF
bronchiectasis and COPD.
DISEASE EXACERBATIONS RESULT FROM
INTERMITTENT CATASTROPHIC FAILURES OF
MUCUS CLEARANCE, OFTEN TRIGGERED BY
VIRAL INFECTIONS
In asthma, viral infections are well-known triggers of bronchos-
pastic episodes (30, 31). While there is no evidence that the
incidence of viral infection is increased in CF, idiopathic bronchi-
ectasis, PCD, or CB/COPD, it is highly likely that viruses “exac-
erbate” these diseases. Epidemiologically, in longitudinal stud-
ies, rhinoviruses, paramyxoviruses, and coronaviruses, as well
as influenza and other viruses, are important triggers of COPD
exacerbations (32). Although detailed longitudinal studies of
viruses in CF are just emerging (33), several studies indicate a
strong relationship between respiratory syncytial virus (RSV)
and rhinovirus infection and pulmonary deterioration (34–36).
Recent studies suggest an abnormal response of airway epithelial
cells from individuals with asthma in response to rhinovirus (37).
Similarly, viruses may trigger acute exacerbations in patients
with other preexisting airway diseases, because the airways are
already inflamed. Because the number and severity of exacerba-
tions are key determinants of declining lung function in both
CF and COPD, it is important to understand the pathophysiology
of virus-induced exacerbations.
A key concept is that many chronic airway diseases are
heterogeneously distributed throughout the lungs. It is likely
that viruses are preferentially delivered to “normal” portions of
diseased lungs due to airflow preservation to these regions. Many
offending viruses, including RSV, infect “normal” ciliated epi-
thelial cells, again biasing infection to more normal regions of
the lung (38, 39). Viral infection upregulates ecto-ATPases,
depleting extracellular ATP (19), which in turn is predicted to
decrease Cl secretion and inhibit mucus clearance. In this
scenario, bacteria residing in “abnormal” regions will spread
(“metastasize”) to these new areas of mucus adhesion/obstruc-
tion, resulting in more diffuse disease and a greater bacterial
burden. Chemokines, cytokines, proteases, goblet cell hyperpla-
sia, and mucus hypersecretion resulting from viral infection fur-
ther contribute to a descending spiral of airway pathology. Ther-
apy to maintain efficient mucus clearance represents a viable
option to mitigate the deleterious effects of viral infection on
lung function and to minimize exacerbation of chronic airway
diseases.
CF AND CB BOTH REFLECT FAILURE OF MUCUS
CLEARANCE, BUT DIFFER IN INITIATING EVENTS,
SEVERITY, EFFICACY OF COUGH, AND STIMULI
PRODUCING CHRONIC INFLAMMATION
There is evidence that mucus dehydration and adhesion occur
in both CF and COPD. In CF, studies using well-differentiated
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Figure 10. Mucus becomes closely apposed to the cell surface in CF.
A photomicrograph of a frozen section of a CF airway. This preparation
prevents artifactual splitting of the luminal contents from the cell surface.
Dark pink and blue mucus granules are visible within the epithelium,
cell nuclei are clear areas, and the basement membrane is the light pink
line below. Alcian blue-PAS stain.
airway epithelial cells in culture demonstrate failure to maintain
adequate ASL hydration (16). In vivo, there is evidence for
subtle inflammation and goblet cell hyperplasia in the nasal
cavity of CF mice, the region that best mimics the human CF
ion transport phenotype (12). In the lower airways of CF mice,
CaCC mediates Cl transport rather than CFTR, and the mice
also do not reprise the accelerated Na transport found in human
CF airways, so there are ion transport correlates to explain the
absence of a lower airway phenotype. However, as also noted
above, overexpression of the  subunit of ENaC in the mouse
airway depleted ASL volume and produced mucus adhesion,
plaques, and plugs (11). Clinical studies of patients with CF
suggest that the % solids concentration in CF secretions is in-
creased (40). Finally, frozen sections of CF airways, a histologic
technique that prevents artifactual splitting of luminal contents
away from the airway wall, demonstrate close apposition of
luminal mucus with the cell surface (Figure 10).
There is less direct data supporting dehydration and mucus
adhesion in COPD. It is important to note that relative dehydra-
tion can be manifest as either less ASL or an increase in the %
Figure 11. Comparison of ASL
volume homeostasis by normal
(Nl) and CF airway epithelial
cultures under phasic motion
conditions. The phasic motion
condition delivers shear stress
to the epithelial surface that
approximates that generated
in vivo by phasic respiration
( 0.5 dynes · cm2). (A ) Con-
focal (x-z) images of Nl (top
panels) and CF (bottom panels)
ASL with time. (B ) ASL height
for normal (open bar) and CF
(filled bar) at 48 h. (C ) Rota-
tional mucus transport at 48 h under static or phasic motion conditions. (D ) Reduction in CF ASL height to below normal level (dashed blue line)
after addition of apyrase to remove ATP but not after 8-SPT. Adapted from Ref. 19, with permission.
solids of materials present in the lumen. Goblet cell hyperplasia
and mucus hypersecretion are prominent in COPD, and new
data suggest that salt and water transport and mucin secretion
are segregated to different cell types in the airway epithelium.
Specifically, ENaC and CFTR are located within ciliated epithe-
lial cells, whereas goblet cells secrete mucins but not ions or
water (41). The data of Verdugo suggest that mucins are secreted
after a pore is formed between the secretory granule and the
plasma membrane and Na within ASL exchanges for Ca2 in
the granule, resulting in hydration and explosive exit from the
granule (42, 43). Thus, relative dehydration of ASL in the CB
airway can reflect a primary increase in the mass of solids on
the airway surfaces due to mucin hypersecretion, or a relative
paucity of liquid, due to abnormal Na absorption and/or Cl
secretion, or both. Perhaps the most compelling data that mucus
dehydration is a problem in COPD are those of Dr. Hogg et al.
that describe mucus adhesion to airway surfaces and mucus
obstruction in the small airways (see Figure 2 and Ref. 9).
Although both CF and COPD are characterized by relative
dehydration and adhesion of mucus, the pathogenic sequence
is very different in the two diseases. In CF, there is an intrinsic
defect in the CFTR Cl secretory pathway and unregulated Na
absorption. These two defects in CF deplete ASL volume, which
is later worsened by chronic infection and mucin hypersecretion.
As noted previously, CF airway epithelial cells in vitro under
static conditions fail to auto-regulate ASL volume (Figure 7).
This would predict rapid depletion of ASL volume and cessation
of mucus transport under basal conditions in CF lungs within
months of life. However, young patients with CF typically do
well for significant intervals, and mucus clearance can be main-
tained, at least in certain regions, for substantial periods (44).
One explanation lies in observations of in vitro ASL volume
regulation under phasic motion conditions that mimicked the
motion of tidal volume breathing in vivo (19). CF cultures under
phasic motion conditions exhibited an increase in ASL volume,
with two key differences from normal cultures (Figure 11). First,
ASL height, although sufficient to maintain mucus transport,
was less in CF, consistent with the absence of adenosine-
regulated CFTR function. Second, addition of apyrase to CF
cultures under phasic motion conditions led to the collapse of
ASL, presumably due to the absence of ATP-stimulated pu-
rinergic receptor–mediated inhibition of ENaC and activation
of CaCC. These data suggest that CF airways are critically vul-
nerable to insults that decrease ATP signaling. Consistent with
the notion that CF exacerbations induced by viruses may be
due to decreased ATP, RSV infection, which stimulated the
breakdown of ATP, abolished the capacity of CF airway epithelia
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to maintain ASL volume under phasic motion conditions,
whereas ASL volume was only moderately reduced by RSV in
normal airway epithelial cells (19). Thus, one major difference
between CF and COPD is that CF airways rely solely on ATP
interaction with P2Y2-R to stimulate CaCC, whereas COPD cells
can hydrate via both the ATP mechanism and via adenosine
interaction with A2b-R to activate CFTR.
Mucus dehydration in COPD is likely multifactorial. As noted
above, goblet cell hyperplasia and mucin hypersecretion per se
may increase the % solids content of ASL, causing relative
dehydration in COPD (45). It is also likely that defects in ion
and water transport contribute. Kreindler and coworkers
reported that cigarette smoke condensates had relatively few
effects on Na transport rates, but inhibited both CFTR and
CaCC-mediated Cl secretion, possibly by inhibiting basolateral
Na-K-2Cl co-transport (46). More studies are necessary to
define the specific mechanisms of cigarette smoke inhibition of
ion transport and also whether nucleotide and nucleoside metabo-
lism and levels are different in the airways of smokers or patients
with COPD. Endogenous cell surface proteases such as prostasin
activate ENaC and accelerate Na absorption (47), and soluble
proteases, including elastase, have similar activity (48, 49). In the
later stages of COPD, neutrophil-derived elastase may activate
ENaC, leading to Na hyperabsorption. Thus, neutrophilic in-
flammation due to cigarette smoking may produce sufficient free
elastase to increase goblet cell number and mucin production and
to elevate Na absorption, causing relative dehydration.
To summarize the differences and similarities between CF
and COPD, we note that CF is the most aggressive form of
chronic mucus obstruction and infection and likely exhibits the
most dehydrated airway mucus. The prediction is that in COPD,
mucus concentrations will be intermediate between normal and
CF, and mucus adhesion less widespread and firm. Since COPD
cells will be able to generate a fluid secretory response via both
CFTR and CaCC, while the CF cell response will be limited to
CaCC, the prediction is that the balance of beneficial versus
harmful effects of chemokines, cytokines, ATP, and adenosine
generated during inflammation will be different. Early in disease,
increased ATP will benefit both CF and COPD by stimulating
CaCC. Late in disease, ATP could be harmful in both, due to
ATP-stimulated mucin release in lungs with existing goblet cell
hyperplasia (50). Importantly, increased adenosine may be more
detrimental in CF, due to potential cAMP-dependent accelera-
tion of Na absorption (51) coupled with an inability to generate
compensatory hydration through CFTR, whereas in COPD, neg-
ative effects of adenosine on ENaC can be offset by A2b-R activa-
tion of CFTR. Bacterial avoidance of host defense and biofilm
Figure 12. Mucus clearance in patients with CF under
baseline conditions and after inhalation of 7% hypertonic
saline (HS). (A ) Whole lung mucus clearance over 60 min.
(B ) Twenty-four-hour clearance without (open bar) or with
(shaded bar) HS. The shaded area with dashed line repre-
sents 24 h clearance  1 SD in normal individuals (n 
12 per group). * Different from basal (P  0.05). Adapted
from Ref. 56, with permission.
formation will be more profound in more concentrated mucus,
producing more aggressive disease in CF (28). Viral infections
will trigger acute exacerbations in both diseases, but the ability
to compensate for reduced mucociliary clearance by coughing
will be less efficient in CF than in COPD. In CF, constant expo-
sure to microbial and inflammatory products drives expansion
of the airway epithelial cell endoplasmic reticulum compartment,
causing greater Ca2-activated cytokine release triggered by G
protein–coupled receptors (52, 53). Constant exposure to bacte-
ria and neutrophilic inflammation in CF, versus intermittent
tobacco smoke and bacteria in COPD, likely results in stronger
induction of the endoplasmic reticulum proinflammatory Ca2
mechanism.
Mucolytic therapy with N-acetylcysteine has no proven benefit
in either CF or COPD (54, 55). This may not be surprising, since
cleaving mucins adherent to cell surfaces without coordinate rehy-
dration may not be effective (imagine “gum stuck on a wall”—
chopping the gum into pieces results in many stuck pieces!).
RESTORATION OF AIRWAY SURFACE HYDRATION
WITH HYPERTONIC SALINE IS EFFICACIOUS IN CF,
AND STRATEGIES TO HYDRATE AIRWAY SURFACES,
OR DRUGS TO RE-DIRECT ION FLOWS, MAY BE
SIMILARLY USEFUL IN COPD
Theoretically, inhaled hypertonic saline (HS) will generate tran-
sient NaCl osmotic gradients on airway surfaces that will draw
water from the submucosal space onto the airway surface. The
maximal effect and durability of HS treatment will reflect the
rate at which NaCl is passively and actively absorbed from airway
surfaces. Two clinical trials of inhaled HS in CF subjects have
been recently reported (56, 57). Donaldson and colleagues found
that 2 wk of inhaled HS (7%, 4 times/day) accelerated particle
clearance from CF lungs (Figure 12), which was associated with
a small improvement in pulmonary function and improved qual-
ity of life (56). Companion studies of Elkins and coworkers
reported that 7% HS twice daily for 1 yr produced similar small
improvements in pulmonary function, but larger (60%) reduc-
tions in acute exacerbations and improvements in quality of life
(57). No serious adverse events were reported in either study,
including significant bronchoconstriction, protracted cough, ac-
quisition of new bacterial organisms, worsening of bacterial den-
sities, or elevated sputum markers of inflammation. Taken to-
gether, the data suggest that HS eliminated or reduced mucus
plugs from relatively few airways, producing only modest
changes in pulmonary function, but that HS accelerated the rate
of mucus clearance in the relatively normal areas of the CF lung.
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Thus, when areas of the CF lung with preserved function were
subjected to insults such as viral infection, which are predicted
to reduce ATP and decrease mucus transport (19), HS would
sustain mucus clearance, minimizing spread of bacterial infection.
In COPD, HS has been used as a tool to induce sputum. Pre-
treatment regimens and safety criteria for patients with COPD
challenged with HS for investigative purposes have been estab-
lished (58–60), and HS appears to be safe for most patients with
COPD, including those with an FEV1 below 50%. There is one
report of the effect of HS on mucociliary clearance in COPD.
Clarke and colleagues used HS as a control arm for an active
drug regimen consisting of hypertonic N-acetylcysteine (61). Both
regimens increased mucus clearance and maintained equal efficacy
over 3 d. Thus, the effects of hypertonic N-acetylcysteine were
precisely mimicked by 7% HS. This study only assessed the acute
effects of HS on mucus clearance and did not measure sustained
effects, which is important, because in vitro studies suggest that
HS in normal airways will have a shorter duration of action than
in CF airways (12). The difference between CF and non-CF exists
because NaCl can diffuse rapidly down the imposed chemical gradi-
ent through open Na and Cl channels in normal airway epithelial
cells, whereas diffusion is slowed in CF cells due to the absence
of an active Cl channel. Thus, additional clinical trials using more
sustained regimens of HS in COPD are needed.
The positive results of HS in CF provide a rational basis for
more sophisticated approaches toward increasing ASL volume
for longer periods of time in both CF and COPD. One option
is the use of nonionic osmolytes such as mannitol or xylitol.
However, a common failing of both ionic and nonionic osmolytes
is that their action is directly proportional to the mass of com-
pound deposited on the airway surface. Given current aerosol
technologies, and assuming a relatively even distribution of aero-
sol droplets over a greatly expanding surface area from proximal
to distal airways, the mass delivered to the small airways is likely
small (62). Because the distal airways are a key site of disease in
both CF and COPD (9), it will be necessary to develop improved
therapies to treat these areas. The use of osmolyte therapy to
validate airway surface rehydration as a therapeutic modality
should stimulate the development and application of more po-
tent pharmacologic agents that can be delivered in doses that
exceed the EC50/IC50 of target receptors and/or channels.
Summary and Conclusion
Mucus clearance is an essential innate immune protective mecha-
nism in the airways. Carol B. Basbaum’s lifetime of work contrib-
uted greatly to our knowledge of the respiratory tract mucus
clearance system and its pathobiology. Recent advances have
increased our understanding of the structure and function of the
mucus clearance apparatus, its homeostatic regulation in normal
airways, and how both genetic and acquired diseases, principally
by affecting airway surface hydration, disrupt its function to
ultimately degrade lung function. Recent clinical trials indicate
that aerosolized hypertonic saline helps to rehydrate airway sur-
faces in patients with CF, improving mucus clearance, decreasing
acute exacerbations, and increasing quality of life. This new
therapy is a palpable reward of the advances in basic science
and points the way toward even better treatments.
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